Veradermics (NYSE:MANE) Stock Price Target Raised at Leerink Partners

Posted by George Bondi on Nov 9th, 2026

Veradermics (NYSE:MANE – Get Free Report) had its price target lifted by investment analysts at Leerink Partners from $135.00 to $150.00 in a report issued on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Leerink Partners‘s price target points to a potential upside of 4.58% from the stock’s current price.

MANE has been the topic of a number of other research reports. UBS Group set a $204.00 price objective on shares of Veradermics in a research note on Thursday, October 22nd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Veradermics in a research note on Friday, August 21st. B. Riley Financial increased their price target on shares of Veradermics from $170.00 to $204.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Needham & Company LLC raised their price target on shares of Veradermics from $164.00 to $172.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Finally, Citigroup reaffirmed a “buy” rating on shares of Veradermics in a report on Tuesday, September 15th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Veradermics has an average rating of “Moderate Buy” and a consensus target price of $172.43.

Read Our Latest Stock Report on Veradermics

Veradermics Stock Up 3.4%

Shares of MANE traded up $4.66 during mid-day trading on Monday, reaching $143.44. The company had a trading volume of 491,920 shares, compared to its average volume of 641,743. The stock has a market capitalization of $5.99 billion and a P/E ratio of -75.49. Veradermics has a 52-week low of $32.00 and a 52-week high of $146.57. The stock has a 50 day moving average of $117.75 and a two-hundred day moving average of $97.17.

Veradermics (NYSE:MANE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, meeting the consensus estimate of ($0.58). On average, sell-side analysts expect that Veradermics will post -2.87 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Montanova Capital, Llc sold 750,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $107.25, for a total transaction of $80,437,500.00. Following the transaction, the director owned 461,033 shares in the company, valued at $49,445,789.25. This trade represents a 61.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John W. Childs sold 100,000 shares of Veradermics stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the completion of the sale, the director directly owned 194,117 shares in the company, valued at $20,793,813.04. This represents a 34.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 961,000 shares of company stock valued at $103,120,220 over the last ninety days.

Hedge Funds Weigh In On Veradermics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Montanova Capital LLC acquired a new stake in Veradermics in the 2nd quarter worth about $512,533,000. Bamco Inc. NY increased its stake in Veradermics by 284.8% during the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock worth $28,225,000 after buying an additional 169,913 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Veradermics during the second quarter valued at approximately $9,835,000. Wellington Management Group LLP acquired a new position in shares of Veradermics during the second quarter valued at approximately $8,425,000. Finally, Alps Advisors Inc. lifted its position in shares of Veradermics by 31.2% in the third quarter. Alps Advisors Inc. now owns 55,356 shares of the company’s stock valued at $6,711,000 after acquiring an additional 13,150 shares in the last quarter.